CL2018002850A1 - Amidas heterocíclicas útiles como moduladores de proteínas. - Google Patents

Amidas heterocíclicas útiles como moduladores de proteínas.

Info

Publication number
CL2018002850A1
CL2018002850A1 CL2018002850A CL2018002850A CL2018002850A1 CL 2018002850 A1 CL2018002850 A1 CL 2018002850A1 CL 2018002850 A CL2018002850 A CL 2018002850A CL 2018002850 A CL2018002850 A CL 2018002850A CL 2018002850 A1 CL2018002850 A1 CL 2018002850A1
Authority
CL
Chile
Prior art keywords
protein modulators
heterocyclic amides
amides useful
useful
heterocyclic
Prior art date
Application number
CL2018002850A
Other languages
English (en)
Spanish (es)
Inventor
Guosen Ye
Yiqian Lian
Adam Kenneth Charnley
Michael G Darcy
Jason W Dodson
Xiaoyang Dong
Terry V Hughes
Jianxing Kang
Lara Kathryn Leister
Yue Li
John F Mehlmann
Neysa Nevins
Joshi M Ramanjulu
Joseph J Romano
Gren Z Wang
Daohua Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2018002850A1 publication Critical patent/CL2018002850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
CL2018002850A 2016-04-07 2018-10-05 Amidas heterocíclicas útiles como moduladores de proteínas. CL2018002850A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319358P 2016-04-07 2016-04-07
US201762461301P 2017-02-21 2017-02-21
US201762461975P 2017-02-22 2017-02-22

Publications (1)

Publication Number Publication Date
CL2018002850A1 true CL2018002850A1 (es) 2018-12-14

Family

ID=58503675

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018002850A CL2018002850A1 (es) 2016-04-07 2018-10-05 Amidas heterocíclicas útiles como moduladores de proteínas.
CL2018003291A CL2018003291A1 (es) 2016-04-07 2018-11-20 Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CL2018003290A CL2018003290A1 (es) 2016-04-07 2018-11-20 Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2018003291A CL2018003291A1 (es) 2016-04-07 2018-11-20 Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CL2018003290A CL2018003290A1 (es) 2016-04-07 2018-11-20 Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).

Country Status (33)

Country Link
US (4) US10981901B1 (ja)
EP (2) EP4032885A1 (ja)
JP (4) JP6746712B2 (ja)
KR (2) KR102527784B1 (ja)
CN (3) CN113549110A (ja)
AU (4) AU2017247798C1 (ja)
BR (2) BR122018070838A8 (ja)
CA (1) CA3019630A1 (ja)
CL (3) CL2018002850A1 (ja)
CO (1) CO2018010727A2 (ja)
CR (2) CR20200044A (ja)
DK (1) DK3440076T3 (ja)
DO (3) DOP2018000217A (ja)
ES (1) ES2921855T3 (ja)
HR (1) HRP20220936T1 (ja)
HU (1) HUE058932T2 (ja)
IL (4) IL295649A (ja)
JO (1) JOP20170083B1 (ja)
LT (1) LT3440076T (ja)
MX (3) MX2020009948A (ja)
MY (1) MY189100A (ja)
NZ (1) NZ745957A (ja)
PE (3) PE20181920A1 (ja)
PH (3) PH12018502151B1 (ja)
PL (1) PL3440076T3 (ja)
PT (1) PT3440076T (ja)
RS (1) RS63462B1 (ja)
SG (3) SG11201808621TA (ja)
SI (1) SI3440076T1 (ja)
TW (3) TWI776806B (ja)
UA (1) UA123407C2 (ja)
UY (1) UY37195A (ja)
WO (1) WO2017175147A1 (ja)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016304899B2 (en) 2015-08-13 2018-11-08 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
AR109788A1 (es) 2016-10-04 2019-01-23 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
US11312772B2 (en) 2017-08-04 2022-04-26 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
CA3077337A1 (en) * 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
EP3692033A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
JP7262451B2 (ja) * 2017-10-05 2023-04-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｓｔｉｎｇアゴニストの投与方法
CN111566119A (zh) 2017-11-10 2020-08-21 武田药品工业有限公司 Sting调节剂化合物以及制备和使用方法
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
WO2019134707A1 (zh) * 2018-01-08 2019-07-11 成都先导药物开发股份有限公司 一种免疫调节剂
JP2021513976A (ja) * 2018-02-16 2021-06-03 ユーシービー バイオファルマ エスアールエル 医薬活性を有する６，５複素二環式環誘導体
US11311528B2 (en) 2018-03-20 2022-04-26 Merck Sharp & Dohme Corp. Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors
CA3093849A1 (en) 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
TWI793294B (zh) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting促效劑化合物
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2021525706A (ja) * 2018-05-25 2021-09-27 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｓｔｉｎｇ活性化剤としての三環式複素環式化合物
KR20210025016A (ko) * 2018-06-28 2021-03-08 지앙수 헨그루이 메디슨 컴퍼니 리미티드 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
MA53438A (fr) 2018-08-24 2021-09-15 Codiak Biosciences Inc Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées
WO2020038387A1 (zh) 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
CN112608331B (zh) * 2018-08-29 2022-03-11 杭州阿诺生物医药科技有限公司 中间体及其在合成sting蛋白激动剂化合物中的应用
JP7254818B2 (ja) 2018-09-06 2023-04-10 第一三共株式会社 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
JP7469308B2 (ja) 2018-12-06 2024-04-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規の医薬製剤
WO2020132566A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting pyrazole agonists and uses thereof
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
US20220056049A1 (en) * 2019-01-07 2022-02-24 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020151682A1 (zh) * 2019-01-23 2020-07-30 成都先导药物开发股份有限公司 一种大环类免疫调节剂
US20220119379A1 (en) * 2019-01-31 2022-04-21 Hitgen Inc. Immunomodulator
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3133314A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
EP3946610A1 (en) 2019-03-28 2022-02-09 Lupin Limited Macrocyclic compounds as sting agonists
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
WO2021000770A1 (zh) * 2019-07-02 2021-01-07 凯复制药有限公司 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
BR112022001125A2 (pt) 2019-07-22 2022-03-15 Lupin Ltd Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos
CN112279835B (zh) * 2019-07-24 2022-07-22 中国医学科学院药物研究所 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途
US20220267364A1 (en) * 2019-07-25 2022-08-25 Shanghai Jemincare Pharmaceuticals Co., Ltd. Heterocyclic amide compound, preparation method therefor and use thereof
JP2022543086A (ja) 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN112521371B (zh) * 2019-09-19 2022-11-25 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ， インコーポレイテッド 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
JP2022549328A (ja) 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞組成物
WO2021068866A1 (en) * 2019-10-10 2021-04-15 Beigene, Ltd. Heterocyclic compounds as sting modulators
CN116813647A (zh) * 2019-11-02 2023-09-29 上海凌达生物医药有限公司 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN112940004B (zh) * 2019-12-11 2022-07-12 中国科学院上海药物研究所 一种杂环化合物及其用途
US20230062932A1 (en) * 2019-12-18 2023-03-02 Ctxt Pty Ltd Compounds
CN113087668B (zh) * 2019-12-23 2022-11-04 中国科学院上海药物研究所 一类苯并咪唑二聚体、其制备方法及用途
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4115909A1 (en) 2020-03-06 2023-01-11 Daiichi Sankyo Company, Limited Antibody-drug conjugate including novel cyclic dinucleotide derivative
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
EP4218826A3 (en) 2020-04-02 2023-10-25 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. CANCER THERAPY METHODS
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
EP4209506A1 (en) 2020-09-02 2023-07-12 Daiichi Sankyo Company, Limited Novel endo-?-n-acetylglucosaminidase
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
CA3192470A1 (en) 2020-09-23 2022-03-31 Tim SOOS Methods of producing extracellular vesicles
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
BR112023014128A2 (pt) 2021-01-15 2023-10-31 Seagen Inc Conjugados de anticorpo-fármaco imunomodulatórios
CN112920172B (zh) * 2021-02-01 2022-03-22 厦门大学 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用
WO2022177307A1 (ko) * 2021-02-17 2022-08-25 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
KR20220117805A (ko) 2021-02-17 2022-08-24 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2022223619A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
EP4346894A1 (en) 2021-05-24 2024-04-10 GlaxoSmithKline Biologicals S.A. Adjuvants
WO2022246597A1 (en) * 2021-05-24 2022-12-01 Forever Millets Limited Imidazopyridine derivatives as sting agonists
KR20240027018A (ko) * 2021-06-25 2024-02-29 볼트 바이오테라퓨틱스 인코퍼레이티드 비스-벤즈이미다졸 sting 효능제 면역접합체 및 이의 용도
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
CN115724838A (zh) * 2021-08-26 2023-03-03 成都先导药物开发股份有限公司 一种适合作为抗体偶联药物效应分子的sting激动剂
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023136589A1 (en) * 2022-01-11 2023-07-20 Bisichem Co., Ltd. Fused heteroaryl hydroxamates as sting agonists
WO2023148129A1 (en) * 2022-02-02 2023-08-10 F. Hoffmann-La Roche Ag Imidazole macrocycles for the treatment of autoimmune disease
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
WO2024009191A1 (en) 2022-07-05 2024-01-11 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024076964A1 (en) * 2022-10-03 2024-04-11 Thomas Jefferson University Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EP1284740B1 (en) 2000-05-19 2008-05-21 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
ES2261453T3 (es) 2000-08-04 2006-11-16 Corixa Corporation Nuevos compuestos inmunoefectores.
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP1378509A4 (en) 2001-03-19 2009-03-25 Ono Pharmaceutical Co DRUGS WITH TRIAZASPIRO ç5.5] UNDECANDERIVATES AS ACTIVE SUBSTANCE
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
CA2481502A1 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
KR20050057670A (ko) 2002-10-24 2005-06-16 글락소 그룹 리미티드 바이러스 감염 치료용 1-아실-피롤리딘 유도체
JP4537315B2 (ja) 2002-11-01 2010-09-01 バイロファーマ・インコーポレイテッド ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法
JP2006511554A (ja) 2002-12-13 2006-04-06 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのピペリジン誘導体
AU2003296992A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
ATE384724T1 (de) 2002-12-13 2008-02-15 Smithkline Beecham Corp Cyclopropylverbindungen als ccr5 antagonisten
DE60323133D1 (de) 2002-12-13 2008-10-02 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
WO2004055012A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
US7452992B2 (en) 2002-12-13 2008-11-18 Smithkline Beecham Corporation Heterocyclic compounds as CCR5 antagonists
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
US20050176792A1 (en) 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
ES2431314T3 (es) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
US7709458B2 (en) 2004-03-15 2010-05-04 David K. R. Karaolis Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1748991A1 (en) 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PL1781662T3 (pl) 2004-08-18 2011-08-31 Pfizer Inhibitory zależnej od RNA polimerazy RNA wirusa zapalenia wątroby typu C, i kompozycje i terapie wykorzystujące je
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
MX2007013415A (es) 2005-05-04 2008-01-15 Hoffmann La Roche Compuestos antivirales heterociclicos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8088806B2 (en) 2005-05-09 2012-01-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
DK2559690T3 (en) 2005-05-10 2016-04-25 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5575636B2 (ja) 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
EP3239178A1 (en) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
ES2475206T3 (es) 2008-02-01 2014-07-10 Takeda Pharmaceutical Company Limited Derivados de oxima como inhibidores de HSP90
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009143039A2 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
WO2013166000A1 (en) 2012-04-30 2013-11-07 Barber Glen N Modulating immune responses
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
DK2342226T3 (en) 2008-09-26 2016-09-26 Dana Farber Cancer Inst Inc HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
BR112012024380A2 (pt) * 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
PT2609118T (pt) 2010-08-23 2017-03-22 Univ Texas Anticorpos anti-ox40 e métodos de utilização dos mesmos
EP2651926A4 (en) 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
JP6220774B2 (ja) 2011-03-31 2017-10-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｉｃｏｓに対する抗体及びその使用
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
EP2748199B1 (en) 2011-08-23 2019-08-28 Board of Regents, The University of Texas System Anti-ox40 antibodies and methods of using the same
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
IN2014MN02492A (ja) 2012-06-08 2015-07-17 Aduro Biotech
MX350418B (es) * 2012-06-27 2017-09-06 4Sc Discovery Gmbh Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central.
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
AP2015008700A0 (en) 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
US10227638B2 (en) 2014-06-02 2019-03-12 Base4 Innovation Ltd. Nucleotide polymorphism detection method
JP6462006B2 (ja) * 2014-06-04 2019-01-30 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド
WO2016007235A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US10023635B2 (en) 2015-03-23 2018-07-17 Jounce Therapeutics, Inc. Antibodies to ICOS
AU2016304899B2 (en) 2015-08-13 2018-11-08 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2016362697B2 (en) 2015-12-03 2018-07-12 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of STING
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
SI3440076T1 (sl) * 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji

Also Published As

Publication number Publication date
AU2018229498B2 (en) 2019-06-27
PT3440076T (pt) 2022-07-29
KR20180132806A (ko) 2018-12-12
TW202246285A (zh) 2022-12-01
JP7119158B2 (ja) 2022-08-16
SG10201900628RA (en) 2019-02-27
KR20180124149A (ko) 2018-11-20
IL285702A (en) 2021-09-30
BR122018070836A8 (pt) 2022-07-19
US11365190B2 (en) 2022-06-21
UY37195A (es) 2017-10-31
CN109608443B (zh) 2021-09-07
DOP2020000018A (es) 2020-03-15
IL261482B (en) 2021-09-30
CL2018003290A1 (es) 2019-02-01
JP7466596B2 (ja) 2024-04-12
JP2020100646A (ja) 2020-07-02
CA3019630A1 (en) 2017-10-12
JP2021105013A (ja) 2021-07-26
MX2020009948A (es) 2021-10-26
UA123407C2 (uk) 2021-03-31
AU2017247798B2 (en) 2019-10-31
BR122018070836A2 (pt) 2019-09-10
BR122018070838A8 (pt) 2022-07-19
US20230071675A1 (en) 2023-03-09
AU2018229498C1 (en) 2020-09-03
AU2020200692A1 (en) 2020-02-20
DOP2020000019A (es) 2020-03-15
CO2018010727A2 (es) 2018-10-22
CN109608443A (zh) 2019-04-12
SI3440076T1 (sl) 2022-09-30
WO2017175147A1 (en) 2017-10-12
TWI777014B (zh) 2022-09-11
US10981901B1 (en) 2021-04-20
US11970480B2 (en) 2024-04-30
CN109071514B (zh) 2021-07-06
PE20181919A1 (es) 2018-12-11
MX2020009947A (es) 2021-10-26
CR20200044A (es) 2020-03-11
AU2018229497C1 (en) 2020-09-03
IL261482A (en) 2018-10-31
US20180105514A1 (en) 2018-04-19
IL261657A (en) 2018-10-31
IL261657B (en) 2021-09-30
JP2019510796A (ja) 2019-04-18
KR102527786B1 (ko) 2023-04-28
EP3440076B1 (en) 2022-06-01
RS63462B1 (sr) 2022-08-31
HUE058932T2 (hu) 2022-09-28
JP6746712B2 (ja) 2020-08-26
CN109071514A (zh) 2018-12-21
AU2017247798A1 (en) 2018-09-27
PH12018502179A1 (en) 2020-06-15
PE20181884A1 (es) 2018-12-07
EP4032885A1 (en) 2022-07-27
EP3440076A1 (en) 2019-02-13
PH12018502202A1 (en) 2020-06-22
CR20200045A (es) 2020-03-11
ES2921855T3 (es) 2022-09-01
HRP20220936T1 (hr) 2022-10-28
NZ745957A (en) 2020-07-31
MX2018012333A (es) 2019-03-07
AU2017247798C1 (en) 2020-08-27
TWI776806B (zh) 2022-09-11
MY189100A (en) 2022-01-25
BR112018070655A2 (pt) 2019-02-05
PH12018502151A1 (en) 2019-07-08
DOP2018000217A (es) 2018-10-31
AU2020200692B2 (en) 2020-08-27
AU2018229497A1 (en) 2018-10-04
US10189820B2 (en) 2019-01-29
PE20181920A1 (es) 2018-12-11
CN113549110A (zh) 2021-10-26
JOP20170083B1 (ar) 2022-03-14
IL285702B (en) 2022-09-01
JP2022166060A (ja) 2022-11-01
AU2018229497B2 (en) 2019-06-27
KR102527784B1 (ko) 2023-04-28
BR122018070838A2 (pt) 2019-09-10
LT3440076T (lt) 2022-09-26
AU2020200692C1 (en) 2021-03-04
SG11201808621TA (en) 2018-10-30
US20210139473A1 (en) 2021-05-13
PL3440076T3 (pl) 2022-09-05
TW201920161A (zh) 2019-06-01
AU2018229498A1 (en) 2018-10-04
SG10201900629VA (en) 2019-02-27
PH12018502151B1 (en) 2019-07-08
IL295649A (en) 2022-10-01
JP6861307B2 (ja) 2021-04-21
DK3440076T3 (da) 2022-07-11
CL2018003291A1 (es) 2019-02-01
TW201738235A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
CL2018002850A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas.
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
MX2016014615A (es) Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
EA201791733A1 (ru) Производные 9h-пирролодипиридина
CY1124655T1 (el) Κρυσταλλικες μορφες και μορφες αλατος ενωσεων οι οποιες ειναι αγωνιστες του ppar
MX2018003294A (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias.
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
DK3472149T3 (da) Heterocykliske prolinamidderivater
EA201892157A1 (ru) Фосфаплатиновые жидкие составы
EA201892425A1 (ru) Гетероциклические амиды, пригодные в качестве модуляторов белков
EA201600032A1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
IT201700033290A1 (it) “letto migliorato”
IT201700068170A1 (it) Composizione disinfettante per uso oftalmico